Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $60.88, for a total value of $243,520.00. Following the sale, the director now owns 82,394 shares of the company’s stock, valued at approximately $5,016,146.72. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Monday, October 16th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.09, for a total value of $71,090.00.
  • On Tuesday, October 17th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $71.10, for a total value of $284,400.00.
  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total value of $65,470.00.
  • On Thursday, September 14th, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.59, for a total value of $262,360.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.85, for a total value of $227,400.00.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up $0.01 during trading hours on Friday, reaching $59.64. The company had a trading volume of 199,387 shares, compared to its average volume of 526,689. Agios Pharmaceuticals, Inc. has a one year low of $39.24 and a one year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.63) EPS. analysts expect that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.

WARNING: “Insider Selling: Agios Pharmaceuticals, Inc. (AGIO) Director Sells $243,520.00 in Stock” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/18/insider-selling-agios-pharmaceuticals-inc-agio-director-sells-243520-00-in-stock.html.

A number of brokerages have recently issued reports on AGIO. SunTrust Banks, Inc. reiterated a “buy” rating and set a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Credit Suisse Group lifted their price target on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Janney Montgomery Scott reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $75.70.

A number of institutional investors have recently made changes to their positions in AGIO. BlackRock Inc. increased its stake in Agios Pharmaceuticals by 8,463.5% in the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after purchasing an additional 2,141,768 shares during the period. FMR LLC increased its stake in Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after purchasing an additional 895,584 shares during the period. Vanguard Group Inc. increased its stake in Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after purchasing an additional 617,379 shares during the period. Alkeon Capital Management LLC purchased a new position in Agios Pharmaceuticals in the 3rd quarter worth approximately $30,489,000. Finally, Janus Henderson Group PLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter worth approximately $20,423,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.